Treatment and biomarker testing patterns,treatment outcomes in a/m NSCLC with and without actionable genomic alterations

Study identifier:D133FR00204

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

Multicenter, non-interventional, observational study of treatment and biomarker testing patterns, treatment outcomes in advanced/metastatic NSCLC with and without actionable genomic alterations in routine clinical practice in Russia

Medical condition

Non-small-cell lung cancer

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

1500

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 31 Mar 2024
Estimated Primary Completion Date: 30 Jun 2026
Estimated Study Completion Date: 30 Jun 2026

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jan 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria